Laquinimod

From Wikipedia, the free encyclopedia - View original article

Laquinimod
Laquinimod.svg
Identifiers
CAS number248282-07-7 N
PubChem216469
ChemSpider11444966 YesY
UNII908SY76S4G YesY
ChEMBLCHEMBL66092 YesY
ATC codeN07XX10
Jmol-3D imagesImage 1
Properties
Molecular formulaC19H17ClN2O3
Molar mass356.803 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N (verify) (what is: YesY/N?)
Infobox references
 
Jump to: navigation, search
Laquinimod
Laquinimod.svg
Identifiers
CAS number248282-07-7 N
PubChem216469
ChemSpider11444966 YesY
UNII908SY76S4G YesY
ChEMBLCHEMBL66092 YesY
ATC codeN07XX10
Jmol-3D imagesImage 1
Properties
Molecular formulaC19H17ClN2O3
Molar mass356.803 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N (verify) (what is: YesY/N?)
Infobox references

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS).

Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide.[1]

The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.[2][3] However, the response to a given dose was discrepant between both studies.[4]

Phase III studies for MS started in December 2007.[5] In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo.[6] However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.[7]

External links[edit]

References[edit]

  1. ^ Tan IL, Lycklama à Nijeholt GJ, Polman CH et al. (April 2000). "Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials". Mult Scler 6 (2): 99–104. doi:10.1191/135245800678827626. PMID 10773855. 
  2. ^ Comi G, Pulizzi A, Rovaris M et al. (June 2008). "Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study". Lancet 371 (9630): 2085–2092. doi:10.1016/S0140-6736(08)60918-6. PMID 18572078. 
  3. ^ Polman C, Barkhof F, Sandberg-Wollheim M et al. (March 2005). "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS". Neurology 64 (6): 987–91. doi:10.1212/01.WNL.0000154520.48391.69. PMID 15781813. 
  4. ^ Keegan BM, Weinshenker BG (June 2008). "Laquinimod, a new oral drug for multiple sclerosis". Lancet 371 (9630): 2059–2060. doi:10.1016/S0140-6736(08)60894-6. PMID 18572062. 
  5. ^ ClinicalTrials.gov NCT00509145 Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
  6. ^ Kresege, Naomi (1 August 2011). "Teva’s Copaxone Successor Fails in Latest Clinical Trial". Bloomberg. Retrieved 2 August 2011. "Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company’s effort to find a successor to an older drug." 
  7. ^ Comi, G.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A.; Rocca, M. A.; Filippi, M.; Allegro Study, G. (2012). "Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis". New England Journal of Medicine 366 (11): 1000–1009. doi:10.1056/NEJMoa1104318. PMID 22417253.  edit